Abstract:Objective: Antipsychotics, such as aripiprazole and risperidone, are often used to treat individuals with schizophrenia. The efficacy as well as safety of aripiprazole in Western populations has been described. The objective of this study is to investigate the efficacy, safety, and tolerability of aripiprazole and risperidone in Chinese Han schizophrenia subjects in mainland China. Method: The 6-week, double-blind, randomized, parallel study was conducted in 5 medical centers in mainland China from November 2007 to March 2011. A total of 279 subjects with a primary DSM-IV diagnosis of schizophrenia were randomly assigned (with a randomization ratio of 1: 1) to aripiprazole (n = 139) or risperidone (n = 140). Efficacy measurements included the Positive and Negative Syndrome Scale (PANSS) total, positive, negative and general psychopathology subscale scores, and Clinical Global Impressions-Severity of Illness (CGI-S), and Improvement scale scores. Extrapyramidal symptoms (EPS), weight gain, serum prolactin level, QTc interval, and self-reported adverse events were also assessed as measures of safety and tolerability. Results: Both the aripiprazole and risperidone groups showed statistically significant improvement of PANSS total, positive, negative, general psychopathology subscale scores, and CGI-S scores from baseline to the endpoint (all p < 0.01). Significant improvement was noted in the first week for both treatment groups. There were no significant differences in efficacy measurements between the two treatment groups. Mean change of PANSS total scores from baseline to the endpoint was -26.8 +/- 18.1 for aripiprazole and -30.0 +/- 17.7 for risperidone, (p = 0.1475). The responder rate was 71% (n = 99) and 76% (n = 107) for aripiprazole and risperidone, respectively, (p = 0.323). The incidences of EPS were similar in the aripiprazole (25%, n = 35) and risperidone groups (24%, n = 34), respectively (p = 0.757). No clinically meaningful effects on QTc interval, QRS duration, or PR interval were observed in either treatment groups. However, the incidence of clinically significant weight gain (p = 0.0118) and hyperprolactinemia (p < 0.001) in the aripiprazole group was significantly lower than in the risperidone group. Conclusion: The study demonstrated that aripiprazole, as well as risperidone, had rapid and persistent efficacy for psychotic symptoms from the first week of therapy. There may be poor efficacy for aripiprazole compared with risperidone for overall improvement, but there were no significant differences in this study. Aripiprazole showed good tolerability with less weight gain and hyperprolactinemia compared with risperidone. The overall efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects were similar to that reported in Western populations. (C) 2014 Published by Elsevier B.V.

Randomized, Double-Blind, 6-Week Non-Inferiority Study of Lurasidone and Risperidone for the Treatment of Schizophrenia.

A double blinded multicenter clinical trial for evaluating the efficacy and safety of aripiprazole and risperidone in the treatment of schizophrenia

Efficacy and Safety of Long-Acting Risperidone on Early Onset Schizophrenia in Adolescent Patients

Double-blind Comparison of Ziprasidone and Risperidone in the Treatment of Chinese Patients with Acute Exacerbation of Schizophrenia

Lurasidone Versus Quetiapine for Cognitive Impairments in Young Patients with Bipolar Depression: A Randomized, Controlled Study

Effect of Lurasidone on Social Functioning in Schizophrenia

Efficacy and Safety of Lurasidone vs. Quetiapine XR in Acutely Psychotic Patients With Schizophrenia in Korea: A Randomized, Double-Blind, Active-Controlled Trial

Risperidone Versus Haloperidol in the Treatment of Acute Exacerbations of Chronic Inpatients with Schizophrenia: a Randomized Double-Blind Study

Single- and Multiple-Dose Pharmacokinetics, Safety and Tolerability of Lurasidone in Healthy Chinese Subjects

Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders

Effect of Lurasidone on Social Functioning in Schizophrenia: Post Hoc Analysis of the JEWEL Study

Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial

A Randomized,open Label and Parallel-Control Study for the Treatment of Refractory Schizophrenia with Risperidone and Clozapine

Study on Efficacy and Safety of Risperidone in Treatment of Different Kinds of Schizophrenia

Comparison the clinical effects and safety of amisulpride and risperidone in the treatment of schizophrenia

Pharmacokinetics and safety of a new generic lurasidone: a phase I bioequivalence study in healthy Chinese subjects

An Open-Label Randomised Comparison of Aripiprazole, Olanzapine and Risperidone for the Acute Treatment of First-Episode Schizophrenia: Eight-week Outcomes.

Efficacy and Safety of the Domestic Risperidone in Patients with Schizophrenia:a Randomized,Double-blind,Controlled Trial

Aripiprazole and risperidone in treatment of the patients with schizophrenia: a randomly clinical trial

A retrospective study of risperidone oral solution versus risperidone tablets in treating schizophrenia

Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial.